Ludwig Enterprises, Inc.

0.0470+0.00 (+0%)

Oct 29, 4:00:00 PM EDT · OTC Markets OTCPK · LUDG · USD

Upcoming Earnings

Report date

≈ -

Key Stats

Market Cap

7.64M

P/E (TTM)

Basic EPS (TTM)

-0.02

Dividend Yield

Recent Filings

8-K

Interim CEO appointment announced

10/1/25Oct 1, 2025

Ludwig Enterprises appointed Jose Antonio Reyes as Interim Chief Executive Officer effective October 1, 2025, while he retains his role as Senior Head of Global Business Development. Reyes, who previously led as CEO from August 2024 to April 2025 and as COO before that, brings over 30 years of leadership across markets, including founding ventures in executive education and strategy. No compensation details are set yet. This internal shift ensures continuity amid leadership transitions.

8-K

New independent director appointed

9/8/25Sep 8, 2025

Ludwig Enterprises appointed Corain McGinn as an independent director on September 5, 2025, to fill board vacancies. McGinn, 56, brings deep executive experience from Fortune 100 firms like Microsoft, Merck, and Novartis, focusing on tech, pharma, and biotech strategies that boost revenue and market entry. His addition bolsters the board's expertise in innovation and transformation. Committees pending.

10-Q

Q2 FY2025 results

8/12/25Aug 12, 2025

Ludwig Enterprises posted no revenue for Q2 FY2025 ended June 30, 2025, with operating expenses climbing 94.3% y/y to $585,622, driven by higher general and administrative costs for marketing and professional services, yielding an operating loss up 94.3% y/y to $585,622 (derived). Net loss widened to $649,444 from $364,191 y/y, as the $117,217 loss on debt extinguishment and $115,129 debt discount amortization outpaced a $172,729 gain from derivative liability fair value changes; net loss exceeded operating loss mainly due to these non-operating items. Cash rose to $142,474 on $637,150 in convertible note proceeds, though free cash flow not disclosed in the 10-Q; total debt stood at $1,760,275 with maturities through 2025 at 8% rates. Stockholders' deficit deepened to $3,402,160 amid ongoing R&D in mRNA tech. Yet funding remains tight.

8-K

CEO resigns with transition notice

7/30/25Jul 30, 2025

Ludwig Enterprises' CEO Charles T. Todd Jr. resigned on July 24, 2025, effective August 23 after a 30-day notice for smooth transition and replacement search. The move stems from no disagreements over operations or policies. Yet the board must now hunt for a new leader fast.

8-K

Board adds finance expert

6/25/25Jun 25, 2025

Ludwig Enterprises bolstered its board on June 23, 2025, appointing Garth Lees-Rolfe as an independent director with over 19 years in finance and accounting. Lees-Rolfe, current CFO of ABLi Therapeutics and former CFO of Inhibikase Therapeutics, brings deep biotech expertise from public and private roles, plus Big Four auditing chops. No family ties to existing leadership. This move sharpens financial oversight amid growth.

About

Ludwig Enterprises, Inc. operates as a genomic technology and health related company in the United States. The company engages in the developing of products that use inflammatory genetic markers to assess the occurrence of inflammation and inflammation related diseases, as well as monitor treatment responses. It also provides Revealia for Life Home Test Kits, that identify the potential to develop chronic inflammatory diseases, such as cancer and heart disease. In addition, the company develop a medical machine learning artificial intelligence technology that uses mRNA inflammatory language to capture an inflammatory snapshot of disease and the body's response to treatment. Ludwig Enterprises, Inc. was incorporated in 2006 and is based in Miami, Florida.

CEO

Mr. Jose Antonio Reyes

IPO

8/3/2012

Website

https://www.ludwigent.com

Employees

Sector

Healthcare

Industry

Medical Devices